Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase IIIB single-arm study of atezolizumab plus nab-paclitaxel in PD-L1-positive unresectable locally advanced or metastatic triple-negative breast cancer
2019-002488-91Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of atezolizumab in triple-negative breast cancer (TNBC), sponsored by Roche. Primary endpoint: Incidence of treatment-emergent Grade ≥3 adverse events. Started Aug 2019; status: completed.
02
Drugs
atezolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2019-002488-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002488-91.